OncoCyte Corp Net Worth
OncoCyte Corp Net Worth Breakdown | OCX |
OncoCyte Corp Net Worth Analysis
OncoCyte Corp's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including OncoCyte Corp's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of OncoCyte Corp's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform OncoCyte Corp's net worth analysis. One common approach is to calculate OncoCyte Corp's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares OncoCyte Corp's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing OncoCyte Corp's net worth. This approach calculates the present value of OncoCyte Corp's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of OncoCyte Corp's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate OncoCyte Corp's net worth. This involves comparing OncoCyte Corp's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into OncoCyte Corp's net worth relative to its peers.
To determine if OncoCyte Corp is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding OncoCyte Corp's net worth research are outlined below:
| OncoCyte Corp had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 1.5 M. Reported Net Loss for the year was (27.78 M) with profit before taxes, overhead, and interest of 116 K. | |
| OncoCyte Corp has about 45.41 M in cash with (23.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38. | |
| Roughly 65.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 175000 shares by Gisela Paulsen of OncoCyte Corp subject to Rule 16b-3 |
OncoCyte Corp uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in OncoCyte Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to OncoCyte Corp's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know OncoCyte Corp's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as OncoCyte Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading OncoCyte Corp backward and forwards among themselves. OncoCyte Corp's institutional investor refers to the entity that pools money to purchase OncoCyte Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Two Sigma Securities, Llc | 2024-12-31 | 13.2 K | |
| Ground Swell Capital, Llc | 2024-12-31 | 10.9 K | |
| Tower Research Capital Llc | 2024-12-31 | 4.3 K | |
| Ubs Group Ag | 2024-12-31 | 2.7 K | |
| Lee Danner & Bass Inc | 2024-12-31 | 1.4 K | |
| Bank Of America Corp | 2024-12-31 | 436 | |
| Jpmorgan Chase & Co | 2024-09-30 | 308 | |
| Bryn Mawr Trust Company | 2024-12-31 | 250 | |
| Bnp Paribas Arbitrage, Sa | 2024-12-31 | 208 | |
| Broadwood Capital Inc | 2024-12-31 | 6.2 M | |
| Awm Investment Company Inc | 2024-12-31 | 775.8 K |
Follow OncoCyte Corp's market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 80.08 M.Market Cap |
|
Project OncoCyte Corp's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.75) | (1.83) | |
| Return On Capital Employed | (0.43) | (0.45) | |
| Return On Assets | (0.33) | (0.35) | |
| Return On Equity | (1.25) | (1.31) |
When accessing OncoCyte Corp's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures OncoCyte Corp's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of OncoCyte Corp's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in OncoCyte Corp's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of OncoCyte Corp. Check OncoCyte Corp's Beneish M Score to see the likelihood of OncoCyte Corp's management manipulating its earnings.
Evaluate OncoCyte Corp's management efficiency
OncoCyte Corp has Return on Asset of (0.1884) % which means that on every $100 spent on assets, it lost $0.1884. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.6532) %, meaning that it generated no profit with money invested by stockholders. OncoCyte Corp's management efficiency ratios could be used to measure how well OncoCyte Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.83 in 2025. Return On Capital Employed is likely to drop to -0.45 in 2025. At this time, OncoCyte Corp's Non Current Assets Total are fairly stable compared to the past year. Other Current Assets is likely to rise to about 1.1 M in 2025, whereas Total Assets are likely to drop slightly above 49.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 3.01 | 5.55 | |
| Tangible Book Value Per Share | (4.66) | (4.43) | |
| Enterprise Value Over EBITDA | (0.49) | (0.51) | |
| Price Book Value Ratio | 0.67 | 0.64 | |
| Enterprise Value Multiple | (0.49) | (0.51) | |
| Price Fair Value | 0.67 | 0.64 |
OncoCyte Corp showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Enterprise Value Revenue 113.7944 | Revenue | Quarterly Revenue Growth (0.73) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific OncoCyte Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on OncoCyte Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases OncoCyte Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
OncoCyte Corp Corporate Filings
| 24th of February 2025 Other Reports | ViewVerify | |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 11th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 10th of February 2025 Other Reports | ViewVerify |
OncoCyte Corp Earnings per Share Projection vs Actual
OncoCyte Corp Corporate Management
| Andrea James | Chief Officer | Profile | |
| Ekkehard MD | Chief Officer | Profile | |
| Joshua Riggs | Interim Officer | Profile | |
| Tony Kalajian | Senior Vice President Chief Accounting Officer | Profile | |
| Andrew Last | Independent Director | Profile | |
| William Annett | Advisor | Profile |
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.